Neonatal Cardiac Arrhythmia: Adenosine vs Amiodarone Emergency Protocol for NICU

Neonatal Cardiac Arrhythmias: Overview and Clinical Significance

Cardiac arrhythmias in neonates, while less common than in older children, can be rapidly life-threatening if not recognized and treated promptly. Supraventricular tachycardia (SVT) is the most common pathological arrhythmia in neonates, followed by atrial flutter, ventricular tachycardia, and congenital heart block. Sustained tachyarrhythmias can lead to congestive heart failure, cardiogenic shock, and death within hours if untreated. This protocol covers the emergency pharmacological management using adenosine, amiodarone, and other antiarrhythmic agents as recommended by AAP, PALS guidelines, and NNF India.

Supraventricular Tachycardia: Recognition and Diagnosis

SVT is characterized by a narrow QRS complex tachycardia with a rate typically above 220 bpm in neonates. The most common mechanism is re-entrant tachycardia through an accessory pathway (Wolff-Parkinson-White syndrome accounts for a significant proportion).

Diagnostic Features on ECG

Feature	SVT	Sinus Tachycardia
Heart rate	Above 220 bpm (often 250-300)	Usually 160-200 bpm
Onset/offset	Abrupt	Gradual
P waves	Absent or retrograde	Present, normal axis
Beat-to-beat variability	Fixed rate	Variable rate
QRS complex	Narrow (unless aberrant conduction)	Narrow
Response to vagal maneuvers	May terminate abruptly	Gradual slowing then acceleration

Emergency Management Algorithm for Neonatal SVT

1. Assess hemodynamic stability: Is the neonate showing signs of shock (poor perfusion, hypotension, lethargy)?
2. If hemodynamically STABLE:
   • Apply vagal maneuvers: ice bag to face (not submerging) for 15-30 seconds; this stimulates the diving reflex
   • If unsuccessful, administer adenosine (see dosing below)
3. If hemodynamically UNSTABLE:
   • Proceed to synchronized cardioversion at 0.5-1 J/kg
   • If no response, increase to 2 J/kg
   • Administer adenosine during cardioversion preparation if IV access is already available
4. If SVT recurs after conversion: Start maintenance antiarrhythmic (amiodarone, propranolol, or flecainide)

Adenosine Protocol: The First-Line Drug for SVT

Dosing

Attempt	Dose	Maximum	Administration
First dose	0.1 mg/kg	6 mg	Rapid IV push with immediate NS flush
Second dose	0.2 mg/kg	6 mg	If no response after 2 minutes
Third dose	0.3 mg/kg	6 mg	If no response after 2 minutes

Administration Technique (Two-Syringe Rapid Push)

1. Draw adenosine into a 1 mL syringe with the calculated dose
2. Draw 5-10 mL normal saline into a second syringe
3. Connect both syringes via a three-way stopcock to the most proximal IV port
4. Ensure continuous ECG recording is running
5. Push adenosine syringe rapidly, immediately followed by the saline flush as fast as possible
6. Observe ECG for rhythm change (brief asystole or sinus rhythm restoration is expected)

Critical Note: Adenosine has a half-life of approximately 10 seconds. If not given as a rapid bolus with immediate flush, the drug will be metabolized before reaching the heart. Slow administration is the most common reason for treatment failure. Never give adenosine through a distal peripheral IV without an adequate flush.

Expected ECG Response

Adenosine causes transient AV nodal blockade. The expected response is a brief period of AV block (which may appear as asystole for 1-5 seconds on the monitor), followed by resumption of sinus rhythm. If the arrhythmia is atrial flutter, adenosine will transiently slow the ventricular rate revealing flutter waves, aiding diagnosis even if it does not terminate the arrhythmia.

Side Effects of Adenosine in Neonates

• Transient bradycardia or asystole (expected and self-resolving)
• Facial flushing
• Bronchospasm (rare; use cautiously in neonates with reactive airway)
• Transient hypotension
• Chest discomfort (cannot be assessed in neonates)

Amiodarone Protocol: For Refractory SVT and Ventricular Tachycardia

Amiodarone is a class III antiarrhythmic with additional class I, II, and IV properties, making it effective for a broad range of arrhythmias. It is used for:

• SVT refractory to adenosine (3 failed attempts)
• Recurrent SVT requiring chronic suppression
• Ventricular tachycardia with or without hemodynamic compromise
• Junctional ectopic tachycardia (JET), particularly post-cardiac surgery
• Atrial flutter resistant to cardioversion

Amiodarone Dosing

Phase	Dose	Route	Duration	Notes
IV Loading	5 mg/kg	IV (central line preferred)	Over 30-60 minutes	Monitor BP and HR closely; may cause hypotension
IV Maintenance	7-15 mcg/kg/min	Continuous IV infusion	24-48 hours	Adjust based on arrhythmia control
Oral transition	5-10 mg/kg/day	PO divided BID	Weeks to months	For long-term arrhythmia suppression

Amiodarone Safety Considerations

• Hypotension: Common during IV loading; slow the infusion rate; may need volume support
• Bradycardia: Can cause significant sinus bradycardia; temporary pacing may be needed
• QT prolongation: Monitor QTc; discontinue if QTc exceeds 500 ms
• Thyroid dysfunction: Amiodarone contains iodine; monitor thyroid function every 1-3 months during chronic therapy
• Hepatotoxicity: Check liver function at baseline and periodically
• Pulmonary toxicity: Rare in neonates at standard doses but monitor for unexplained respiratory deterioration
• IV site: Highly irritant; central line strongly recommended; peripheral administration can cause severe phlebitis

Ventricular Tachycardia in Neonates

Neonatal VT is less common than SVT but more immediately dangerous. Causes include myocarditis, electrolyte disturbances (hyperkalemia, hypomagnesemia), long QT syndrome, cardiac tumors (rhabdomyoma), and cardiomyopathy.

VT Management Protocol

1. Pulseless VT: Defibrillation at 2 J/kg (unsynchronized); CPR; epinephrine per NRP protocol
2. VT with pulse but hemodynamically unstable: Synchronized cardioversion at 0.5-1 J/kg; escalate to 2 J/kg if needed
3. VT with pulse, hemodynamically stable: Amiodarone 5 mg/kg IV loading over 30-60 minutes; or lidocaine 1 mg/kg IV bolus followed by infusion at 20-50 mcg/kg/min
4. Correct underlying causes: Check and normalize potassium, magnesium, calcium; treat myocarditis; evaluate for long QT syndrome

Lidocaine for Neonatal VT

Parameter	Specification
Loading dose	1 mg/kg IV over 2-5 minutes
Maintenance infusion	20-50 mcg/kg/min
Maximum serum level	5 mcg/mL
Key toxicity	CNS depression, seizures at toxic levels; reduce dose in hepatic dysfunction

Other Antiarrhythmic Agents in the Neonatal Armamentarium

Drug	Class	Dose	Primary Use
Propranolol	II (beta-blocker)	0.5-1 mg/kg/dose PO q8h	SVT prophylaxis, WPW
Flecainide	IC	2-4 mg/kg/day PO divided BID	Refractory SVT, atrial flutter
Digoxin	Cardiac glycoside	Loading: 20-30 mcg/kg divided; Maintenance: 5-8 mcg/kg/day	SVT rate control (avoid in WPW)
Procainamide	IA	5-15 mg/kg IV over 30-60 min	Atrial flutter, VT
Esmolol	II (ultra-short acting)	100-500 mcg/kg/min IV infusion	Acute SVT rate control

Electrical Cardioversion and Defibrillation

When pharmacological therapy fails or the neonate is hemodynamically unstable:

• Synchronized cardioversion (for SVT, atrial flutter, VT with pulse): Start at 0.5-1 J/kg; increase to 2 J/kg if needed
• Defibrillation (for pulseless VT, VF): 2 J/kg unsynchronized; increase to 4 J/kg for subsequent attempts
• Use infant-sized paddles or self-adhesive pads
• Ensure synchronization mode is engaged for cardioversion (prevents shock on T-wave)
• Provide sedation (ketamine 1-2 mg/kg IV) before elective cardioversion when possible

Indian NICU Considerations

Neonatal arrhythmia management in Indian NICUs requires preparedness at multiple levels. Key considerations include:

• Adenosine availability: ensure cold-chain storage where required; verify expiry dates regularly
• 12-lead ECG capability: essential for accurate arrhythmia diagnosis; portable ECG machines should be available in all Level II and III NICUs
• Pediatric cardiology consultation: telemedicine capabilities for ECG interpretation when on-site expertise is unavailable
• Defibrillator readiness: all NICUs should have a defibrillator with pediatric paddles; staff should be trained in its use
• HEAMAC neonatal care resources support Indian NICUs in maintaining emergency arrhythmia protocols and ensuring access to essential antiarrhythmic medications

Conclusion

Neonatal cardiac arrhythmias demand rapid diagnosis through 12-lead ECG, immediate assessment of hemodynamic stability, and stepwise pharmacological intervention. Adenosine remains the first-line drug for SVT conversion, while amiodarone serves as the versatile second-line agent for refractory SVT, VT, and other complex arrhythmias. Every NICU should maintain pre-calculated adenosine dosing charts, ensure rapid push technique training for all staff, and have amiodarone and cardioversion equipment immediately available for arrhythmia emergencies in neonates.